Clinical Trial

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Study acronym: SIZOMUS
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-12-18; most recent amendment 2025-09-01.
Status change: Not Yet Recruiting → Recruiting 2022-02-17
Trial Details
NCT Number NCT03783416
Lead Sponsor Queen Mary University of London
Collaborators: Takeda Pharmaceuticals International, Inc.
Conditions Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Enrollment 72 participants
Start Date 2020-06-15
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-04